In late July, the Government Accountability Office released a report on how the lack of effective communications between the Drug Enforcement Agency and both pharmaceutical distributors and chain pharmacy headquarters has impacted legitimate access to pain medicines. "The agency’s report further validates the need for bipartisan, bicameral legislation," according to NACDS.
McKesson on Thursday reported increased revenues for the first quarter, which ended June 30. At $47.5 billion, revenues were up 9%, compared with $43.5 billion a year ago. First-quarter earnings per diluted share from continuing operations was $2.50 compared with $1.76 a year ago.
Hikma Pharmaceuticals on Wednesday announced its acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane (together, “Roxane” — an American specialty generics company) from Boehringer Ingelheim for about $2.65 billion.
Voters from all political parties support sunshine legislation that would make promote transparency in generic prescription drug payments by pharmacy benefit manager corporations, according to a national survey from the National Community Pharmacists Association released Tuesday.
Sandoz on Tuesday announced the launch of a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) in 1-mg strength. Sandoz expects to have 180-day generic drug marketing exclusivity for the 1-mg strength.
On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.